What Keppra 750mg Treats: Main Uses and Benefits

Keppra 750mg is used to manage epilepsy, a condition characterized by symptoms of excessive electrical activity in the brain. The medicine is applied across therapeutic domains involving the symptoms of unprovoked seizures.

This medication is generally used to address three primary types of seizure events: partial-onset seizures (focal seizures), myoclonic seizures, and primary generalized tonic-clonic seizures. It is relevant in situations where individuals experience recurrent or episodic seizure manifestations. The medication helps manage the frequency and severity of these episodes, which supports general daily functioning.

"The medication is applied when symptoms create noticeable physiological strain and when supportive symptom management is appropriate."

The medicine can be used on its own for certain newly diagnosed partial-onset seizures or is relevant for easing symptoms when combined with other medicines. In both cases, it assists with maintaining functional stability during symptomatic periods.

Quick Fact: Relevant for Recurrent Seizure Activity

Regulatory References

1. European Medicines Agency overview

The eligibility for Keppra (levetiracetam) is determined by age, hypersensitivity status, and kidney function, according to official regulatory labeling.

Populations for Whom Use is Contraindicated

Keppra is contraindicated in patients with a known hypersensitivity or allergic reaction to the active substance, levetiracetam, or to any other pyrrolidone derivatives.

Age-Related Eligibility Rules

The medicine is generally approved for adults and adolescents ge 16 years of age for monotherapy and adjunctive therapy across its labeled uses. For children, the minimum approved age for adjunctive therapy for partial-onset seizures is 1 month of age. Use is not established in infants less than 1 month old. Furthermore, the 750 mg tablet formulation is not adapted for use in children under 6 years due to dosing constraints.

Condition-Specific Eligibility Rules

Use is highly conditional in patients with renal impairment. Because levetiracetam is primarily cleared by the kidneys, any degree of compromised kidney function requires that the dose must be individualized and adjusted based on the patient’s estimated creatinine clearance. For individuals with severe hepatic impairment, a dose adjustment may also be required if there is coexisting kidney dysfunction.

Pregnancy and Lactation Eligibility

Use during pregnancy is permitted, but official labeling recommends close monitoring and potential dose adjustment as plasma levels may decrease, particularly during the third trimester. The drug is excreted into human milk, and the manufacturer recommends women do not breastfeed during therapy due to the potential for adverse effects in the infant.

Interactions with other medicines and products

Keppra (Levetiracetam) possesses a regulatory profile characterized by a low potential for pharmacokinetic drug-drug interactions, primarily because its elimination pathway is largely independent of the hepatic Cytochrome P450 (CYP) enzyme system. The official prescribing information indicates that Levetiracetam does not significantly inhibit or induce major CYP isoenzymes, confirming it does not generally affect the plasma concentrations of commonly co-administered medicines, including oral contraceptives or other antiepileptic drugs.

Documented Interaction Patterns

The most significant interaction documented is a pharmacodynamic effect involving Central Nervous System (CNS) depressants, including alcohol. Co-administration may lead to additive effects such as increased somnolence and fatigue, a warning noted in official regulatory documents.

Exposure-Modifying Interactions

Substance / Class	Regulatory Outcome	Classification Detail
Enzyme-Inducing AEDs	Increase in apparent clearance of Levetiracetam	Pharmacokinetic Interaction
Probenecid	Reduction in renal clearance of inactive metabolite	Transporter Interaction
Food	Delays Tmax and reduces Cmax (no change in total bioavailability)	Pharmacokinetic Interaction

The labels specify that there are no formal contraindicated combinations based on drug interaction risk. Furthermore, the drug's clearance is known to be reduced in patients with renal impairment, a population-specific consideration that necessitates appropriate adjustment as written in the official instructions.

Keppra 750mg (Levetiracetam) exerts its action through a distinctive biological process that modulates activity in central nervous system ( CNS) circuits primarily through presynaptic interactions.

Targeting the Synaptic Vesicle Glycoprotein 2A (SV2A)

The mechanism involves the selective and saturable binding to SV2A, a protein integral to the membrane of presynaptic vesicles. This interaction affects the function of the vesicle machinery responsible for neurotransmitter release.

Restriction of High- Frequency Neurotransmission

The SV2A modulation specifically restricts the exocytosis (release) of excitatory neurotransmitters, such as glutamate, primarily during periods of excessive, high-frequency neuronal firing. This action initiates a cascade that reduces the transfer of chemical signals across the synapse during high-frequency transmission in the CNS circuits.

Resulting CNS Functional Modification

By influencing the release of chemical signals at the synapse, Levetiracetam functionally limits signal transmission efficiency between neurons in hyperactive circuits. The resulting physiological consequence is the functional modification of neuronal network activity, altering the characteristics of hyperexcitable signaling patterns.

How to use Keppra 750 mg — Official Administration Guidelines

Keppra is an Antiepileptic Drug (AED) prescribed based on precise rules regarding its administration, dosing, and schedule.

Administration and Dosage

Administration Route	Oral (Tablets/Solution) or Intravenous (IV) (Temporary only).
Standard Adult Dose (IR)	Begins at 500 mg twice daily; may be increased in 500 mg twice daily increments every two weeks to a maximum of 1500 mg twice daily (3000 mg total/day).
Frequency	The medicine is taken twice daily in two equally divided doses.
Intake Condition	Tablets may be taken with or without food. Film-coated tablets must be swallowed whole.

---

Special Procedural Instructions

Official instructions require specific dose adjustments for certain populations and procedures:

• Renal Impairment: Dosage must be individualized according to the patient’s estimated creatinine clearance (CrCl), as the drug is primarily eliminated by the kidneys. For example, severe impairment (CrCl < 30 mL/min) requires a dose reduction to 250 mg to 500 mg every 12 hours.
• Dose Titration: Treatment always begins with a low dose and is gradually increased to the recommended maintenance level.
• Discontinuation: If treatment must be stopped, it is recommended that the dose be gradually withdrawn (tapered) over several weeks to avoid abrupt changes.
• Missed Dose: If a dose is missed, the patient should take the next scheduled dose as usual, and should not double the dose to make up for the missed one.
• Route Switch: Conversion between the oral form and the intravenous form should be done directly, maintaining the equivalent total daily dosage and frequency.

Research Evidence / Overview of Studies for Keppra 750mg

The available research provides context on how Levetiracetam was studied for specific clinical settings and patient groups. The evidence landscape primarily consists of Randomized Controlled Trials (RCTs), which are widely used in clinical research, along with long-term follow-up studies and comprehensive reviews. This summary focuses only on the structure and patterns of these studies, without offering any clinical advice.

---

Evidence from Clinical Trials for Partial-Onset Seizures

Researchers utilized several short-term, placebo-controlled RCTs to study this medicine was observed in people experiencing partial-onset seizures (focal seizures). Research was evaluated in settings where the medicine was observed in combination with other anti-seizure medications (adjunctive use) and as a single treatment (monotherapy) for newly diagnosed cases. The studies monitored outcomes describing episodic or acute changes, and findings describe patterns observed in the studies where participants receiving the study medicine reported changes measured during the study period compared to those receiving placebo. Pivotal controlled trials were conducted over short follow-up durations, and these results apply only to the populations studied during that specific timeframe.

---

Evidence from Clinical Trials for Generalized Seizure Types

For myoclonic seizures and primary generalized tonic-clonic seizures (PGTCS), the medicine was studied for its adjunctive use primarily through dedicated, short-term, placebo-controlled RCTs. These studies monitored outcomes reflecting daily functioning or activity level, such as the change in the number of seizure days per week. Findings indicate patterns where participants receiving the medicine experienced changes measured during the study period that differed from the placebo group. Since the core evidence is based on one primary controlled trial for each generalized seizure type, the follow-up durations were limited.

---

Gaps and Uncertainties in the Research Landscape

While the main research studies used in the regulatory context are short-term RCTs, there are corresponding open-label extension studies where patients was observed in for longer periods. However, the long-term effects are not fully established by the rigorous, controlled research methods. Comparative evidence is lacking as comparative evidence against all other current options is limited. The evidence base also shows that data for certain groups remain insufficient when considering the medicine as a monotherapy (used alone) for all specific types of seizures.

Key Studies & References

1. Levetiracetam tablet, film coated - DailyMed (Official FDA Labeling)

Common questions about Keppra 750mg (FAQ)

---

Q: Is Keppra 750mg an antidepressant?

A: No. Official documents classify the active ingredient in Keppra, levetiracetam, as an Antiepileptic Drug (AED), also known as an anticonvulsant. Its approved uses are specifically for treating certain types of epileptic seizures, not for treating depression.

---

Q: What is the main difference between Keppra and Levetiracetam?

A: Levetiracetam is the active substance contained in the medicine and is the generic name for the compound. Keppra is the brand name under which the product is marketed. All regulatory information regarding the medicine's use and safety applies to the active ingredient, Levetiracetam.

---

Q: How long does it usually take to feel the effects of Keppra 750mg?

A: Studies on the drug’s pharmacokinetics indicate that the medicine is rapidly absorbed after being taken, and the highest concentration in the blood is typically reached in about one hour for the immediate-release tablet. Steady-state concentrations—the concentration needed to provide a stable effect—are generally achieved within approximately one to two days.

---

Q: Is Keppra 750mg only for epilepsy, or does it treat other conditions too?

A: The medicine is officially approved and indicated only for the treatment of specific types of epileptic seizures, including partial-onset, myoclonic, and primary generalized tonic-clonic seizures. Official prescribing information does not list indications for other conditions.

---

Q: Can Keppra 750mg affect your mood or behavior?

A: Yes, regulatory warnings indicate that this class of medicine may be associated with new or worsening behavioral abnormalities, such as aggression, irritability, or depression. There is also an associated risk of suicidal thoughts or behavior. Regulatory warnings indicate that changes in mood or behavior may occur, and these should be noted.

---

Q: What is the connection between Keppra and kidney function?

A: Keppra is primarily eliminated from the body by the kidneys. Due to its elimination pathway, official prescribing information notes that dosage adjustments are necessary and should be individualized for patients who have impaired kidney function.

---

Q: Does Keppra 750mg have any known interactions with herbal supplements?

A: Official regulatory documents note that Keppra has a low potential for affecting the concentrations of many other drugs. However, there is often insufficient formal regulatory data on the specific effects of combining Keppra with various herbal products or complementary medicines. Regulatory documents state that patients should inform their healthcare provider about all supplements being taken.

---

Q: Is Keppra a drug that needs routine blood monitoring?

A: Therapeutic drug monitoring—measuring the specific amount of the drug in the blood—is not routinely established for Keppra. Dosage is generally managed based on the patient's clinical response and how well they tolerate the medicine, though monitoring of kidney function may be needed.

---

Q: What does the research say about Keppra's effect on sleep?

A: The most common reported adverse effect related to sleep is somnolence, which means sleepiness or drowsiness. Regulatory documents also cite a need for further research to fully understand the drug's overall effects on sleep quality.

---

Q: Is Keppra considered a 'controlled substance'?

A: No. According to the U.S. Drug Enforcement Administration (DEA), the active ingredient Levetiracetam (Keppra) is not classified as a controlled substance and is not scheduled.

---

Q: What is the difference between Keppra and Keppra XR?

A: Keppra is an immediate-release (IR) tablet formulation that is typically taken twice daily. Keppra XR is an extended-release (ER) tablet formulation that is designed to release the active ingredient slowly over time, allowing it to be typically taken once daily.

---

Q: Is Keppra 750mg used to prevent migraines?

A: No. The official indications and usage approved by regulatory bodies are solely for the treatment of specific types of epileptic seizures. Keppra is not officially approved or indicated for the prevention or management of migraines.

---

Q: What is the purpose of the 750mg tablet being scored?

A: Some strengths of Keppra tablets may have a score line to assist in manufacturing. However, official administration instructions specify that all film-coated tablets should be swallowed whole and should not be chewed or crushed.

---

Q: What happens when Keppra 750mg is discontinued?

A: If the medicine is stopped too quickly (abrupt discontinuation), it can increase the risk of seizures or potentially lead to a condition called status epilepticus (a prolonged seizure). Regulatory documents state that if the medicine is discontinued, the dose should be gradually withdrawn over several weeks to avoid potential risk.

---

Q: Does Keppra 750mg have any effect on blood pressure?

A: Official warnings note a potential for a temporary increase in diastolic blood pressure in infants and children during treatment.

---

Q: Does Keppra 750mg have any effect on the results of any lab tests?

A: Official documents cite a potential risk for hematologic abnormalities (blood disorders). Rare reports have also suggested temporary and reversible changes in liver function tests in some cases.

---

Q: What is the status of the 750mg dose for an adult?

A: The maximum recommended maintenance dose for an adult is 1500 mg taken twice daily, totaling 3000 mg per day. Since 750 mg taken twice daily totals 1500 mg per day, this dose falls in the mid-to-upper end of the recommended therapeutic maintenance range.

---

Q: Can Keppra 750mg cause vision changes?

A: While not listed as a common effect, regulatory postmarketing reports have noted adverse reactions that include visual disturbances such as blurred vision and diplopia (double vision).

Storage and Disposal Requirements for Keppra 750 mg

Keppra (levetiracetam) 750 mg film-coated tablets must be stored according to specific regulatory conditions to maintain product integrity and safety.

---

Storage Conditions

• Temperature: Store at controlled room temperature, which is between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. Do not store above 25 C.
• Protection: The medication must be protected from excessive heat and moisture. Do not freeze the tablets.
• Container: Store the tablets in their original container and ensure the container is kept tightly closed.
• Child Safety: Keep the medicine out of the reach and sight of children at all times.

---

Disposal Instructions

Unused or expired Keppra must be disposed of properly. Do not flush the tablets down the toilet or throw them into household trash, as this is restricted for environmental protection. The preferred method for discarding unneeded medicine is through an approved drug take-back program or by consulting a local waste disposal company.